厄贝沙坦治疗轻中度原发性高血压的临床研究  

Oinical Study of Irbesartan on Treating Mild to Moderate Essential Hypertension

作　　者：曾群英[1] 王礼春[1] 廖新学[1] 陶军[1] 李玉杰[1] 陈国伟[1] 杨惜泉[1] 

机构地区：[1]中山大学附属第一医院心内科,广州510080

出　　处：《中国医药导刊》2002年第3期195-197,共3页Chinese Journal of Medicinal Guide

摘　　要：目的:探讨厄贝沙坦治疗轻、中度原发性高血压的临床效应和安全性。方法:119例轻中度原发性高血压随机单盲分为两组,厄贝沙坦(治疗)组:60例,150～300mg/d口服,6周后未达显效者,加双氢氯噻嗪(HCTZ)12.5mg/d疗程半年。氯沙坦(对照)组:59例,50～100mg/d口服,6周后未达显效者,加服HCTZ12.5mg/d,疗程半年。治疗前后均进行偶测血压、动态血压(ABPM)、肝肾功能、生化、血浆肾素活性(PRA)、血管紧张素Ⅱ(AngⅡ)、醛固酮(Aldo)、内皮素(ET)等检查,并观察心脑事件发生情况及药物不良反应。结果:治疗组总有效率81.7％(49/60例),降压幅度24.6/14.5mmμg,谷/峰(T/P)比值:收缩压(SBP)0.81。舒张压(DBP)0.76,6周后未达显效,加服HCTZ2周者,达显效27.0％(10/36例);对照组总有效率80.7％(47/59例)、降压幅度24.2/14.1mmμg,T/P比值SBP0.79、DBP0.75,6周后未达显效,加服HCTZ2周达显效者24.3％(9/37例),两组降压疗效均相似(P均>0.05)。两组治疗后PRA、AngⅡ均较治前升高(P<0.05～0.01)Aldo,ET均较治疗前降低(P<0.05),但4项指标组间比较无显著差异(P>0.05),半年随访,两组心脑事件发生率相似,不良反应轻微。结论:厄贝沙坦是一种降压效果可靠、作用持久、稳定、安全、耐受性好,服药方便(1次/日),可作为治疗轻、中度原发性高血压?Objective: To explore the clinical effect and safety of irbesartan on treating mild to moderate essential hypertension. Methods: 119 cases were assigned to two groups randomly. One group(n = 60) was treated with irbesartan 150-300mg, and the other was treated with losartan 50 -100mg once daily. Hydrochlortiazide (HCTZ) 12.5mg per day was prescribed to the cases in whom the effect of rteatment was not significant in 6 weeks. All cases were followed up half a year. Ambulatory blood pressure, renal and hepatic funtion, plasmal electrolyte, plasma rennin activity (PRA), plasma levels of angiotension Ⅱ( Ang Ⅱ ), Aldosterone(Aldo) and endeothelin (ET) were measured before and after the therapy. Cardiocerebral events were monitored. Result: The total effective rate, amplitude of blood pressure reduced, T/ P ratio of systolic and diastolic blood pressure were 81.7% (49/60), 24.6/ 14.5mmHg, 0.81 and 0.76 respectively in irbesartan group, and that were 80.7% (47/59), 24.2/14.1 mmHg, 0.79and 0.75 respectively in losartan group. The significant effective rate in the cases added HCTZ was 27.0% (10/36) in 2 weeks in irbesartan group, and that was 24.3% (9/37) in losartan group. PRA and Ang Ⅱ elevated after the therapy (P < 0.05- 0.01), while Aldo and ET decreased (P < 0.05) in both groups, but there were no significant differences between the two groups (P > 0.05). The cardiocerebral events and adverse reactions of two groups were similar and mild in half a year' s treatment. Conclusion: Irbesartan is a safe AT1 antag-nost. It has a long and steady antihypertensive effect, also shows a good tolerant profile.

关 键 词：原发性高血压 厄贝沙坦 氯沙坦 高血压 EH 给药方法 疗效 不良反应 

分 类 号：R544.1[医药卫生—心血管疾病]